Business context and reporting period
This Form 10-Q is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp., for the quarter ended September 30, 2021. Ekso designs and sells medical and industrial exoskeleton products through its EksoHealth and EksoWorks segments. Financial amounts below are in U.S. dollars; statements report amounts in thousands unless noted.
Financial performance and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $3.05 million | $2.90 million | $7.17 million | $6.63 million |
| Gross profit / margin | $1.81 million / 59% | $1.81 million / 63% | $4.33 million / 60% | $3.71 million / 56% |
| Operating loss | $2.79 million | $2.42 million | $9.28 million | $10.29 million |
| Net income (loss) | $(1.96) million | $2.45 million | $(6.90) million | $(11.85) million |
| Cash used in operations | Not provided for the quarter | $8.08 million | $7.02 million |
At September 30, 2021, cash was $43.44 million, including $2.00 million required to remain available under the secured loan liquidity covenant; management estimated unrestricted cash at $41.44 million. Working capital was $44.4 million. Notes payable, net, were $1.99 million, due in 2023; the company reported compliance with loan covenants. Total liabilities were $11.67 million and stockholders’ equity was $39.06 million.
Changes versus comparable periods
- Q3 revenue rose 5%, mainly from higher EVO vest sales in EksoWorks. EksoHealth generated $2.72 million and EksoWorks $0.33 million. Management reported 16 EksoNR units booked.
- Q3 gross margin fell from 63% to 59%, attributed to higher EksoHealth service parts and labor costs and product mix. For the nine-month period, margin improved to 60% from 56%, primarily on improved EksoWorks production costs and a lower share of collaborative-arrangement revenue.
- Nine-month operating loss narrowed by $1.02 million. Operating expenses declined 3%, including lower sales and marketing costs and no repeat of 2020 goodwill impairment or restructuring charges.
- Nine-month net loss improved by $4.95 million, but results included a $2.01 million noncash warrant-revaluation gain and a $1.10 million gain from PPP loan forgiveness. Warrant revaluation gains and losses are stock-price-sensitive and can make reported earnings volatile.
- Cash increased by $30.58 million, principally because financing activities provided $38.71 million. The company raised net proceeds of $36.5 million in a February equity offering, received $0.7 million from its ATM offering, and $1.4 million from warrant exercises. Shares outstanding increased from 8.35 million at year-end 2020 to 12.66 million at September 30, 2021.
Outlook, risks and unusual items
Management said available unrestricted cash should fund operations beyond one year from issuance of the financial statements; it provided no quantitative revenue, earnings or margin guidance. The company shifted its medical-device commercial model in 2021 from rentals toward subscriptions intended to renew annually. Deferred revenue was $2.74 million, and non-cancellable subscription backlog was $1.10 million; deferred revenue recognition was expected to be approximately $0.44 million for the rest of 2021, $1.06 million in 2022 and $1.24 million thereafter.
Risks highlighted include COVID-19 effects on customer demand and clinical activity, shortages and longer lead times for semiconductors and other components and manufacturing services, and possible supply-chain disruption related to the pandemic or U.S.-China trade tensions. Foreign-currency fluctuations are also a risk; the company does not hedge currency exposure. Purchase obligations were $2.70 million, primarily for inventory and manufacturing services, and total disclosed contractual obligations were $5.25 million. Management said pending legal matters were not expected to have a material adverse effect and reported no material legal proceedings. Disclosure controls were assessed as effective.
Key facts for investors to verify
- Confirm the filing entity: the supplied 10-Q is for Ekso Bionics Holdings, Inc., not Chronoscale Holdings Corp.
- Assess whether revenue growth and the 16 EksoNR bookings translate into sustained sales, particularly as the subscription model develops.
- Track operating cash burn against management’s liquidity assessment and the $2.00 million minimum-cash covenant.
- Review the effects of the February equity offering, outstanding warrants and further potential share issuance on dilution and reported earnings.
- Monitor gross-margin trends, supply availability, deferred-revenue conversion and the timing of the $2.70 million purchase obligations.